by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Tau pathology impacts neurodegeneration and cognitive decline in Alzheimer’s disease (AD), with the dorsal raphe nucleus (DRN) being among the brain regions showing the earliest tau pathology. As a serotonergic hub, DRN activity is altered...
by Clinical Neuropsychologist | Thursday, February 6, 2025 | Dementia
Abstract Understanding of the biology of Alzheimer’s disease (AD) has long been fragmented, with various investigators concentrating on amyloid beta (Aβ) or tau, inflammation, cell death pathways, misfolded proteins, glia, and more. Yet data from multiple...
by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION The Alzheimer’s Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer’s disease (AD) versus non-AD...
by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION Research on somatic and germline mutations in Chinese individuals with early-onset Alzheimer’s disease (EOAD) has been limited. METHODS We conducted whole-genome sequencing of blood DNA from 108 patients with EOAD and 116 controls. The...
by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION This study aimed to investigate the differential roles of various plasma biomarkers in a stepwise diagnostic strategy for Alzheimer’s disease (AD). METHODS A total of 2984 participants, including 666 cognitively unimpaired (CU), 2032 with...
by Clinical Neuropsychologist | Monday, February 3, 2025 | Dementia
Abstract INTRODUCTION Identifying the link between early Alzheimer’s disease (AD) pathological changes and neurodegeneration in asymptomatic individuals may lead to the discovery of preventive strategies. We assessed longitudinal brain atrophy and cognitive...
